We currently recommend a minimum test panel for hematology comprising (1) a complete or full blood count (CBC/FBC, representing the United States, European, United Kingdom, Australian nomenclature), (2) routine coagulation tests (prothrombin time [PT] and activated partial thromboplastin time [APTT]), (3) fibrinogen, and (4) D-dimer (optional: other associated tests such as fibrin/fibrinogen degradation products and fibrin monomers as locally available or supported). We also recommend a series of biochemistry and other tests, including markers for inflammation, electrolyte disturbance, liver dysfunction, and renal and cardiac damage, which would reflect the development of viral sepsis, systemic inflammatory response syndrome, and/or MOF, which are all conditions associated with an extraordinarily enhanced risk of thrombotic coagulopathies.
Recommendations for Minimal Laboratory Testing Panels in Patients with COVID-19: Potential for Prognostic Monitoring
Lippi, Giuseppe
2020-01-01
Abstract
We currently recommend a minimum test panel for hematology comprising (1) a complete or full blood count (CBC/FBC, representing the United States, European, United Kingdom, Australian nomenclature), (2) routine coagulation tests (prothrombin time [PT] and activated partial thromboplastin time [APTT]), (3) fibrinogen, and (4) D-dimer (optional: other associated tests such as fibrin/fibrinogen degradation products and fibrin monomers as locally available or supported). We also recommend a series of biochemistry and other tests, including markers for inflammation, electrolyte disturbance, liver dysfunction, and renal and cardiac damage, which would reflect the development of viral sepsis, systemic inflammatory response syndrome, and/or MOF, which are all conditions associated with an extraordinarily enhanced risk of thrombotic coagulopathies.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
